查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1618228

生物过程分析仪市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032 年

Bioprocess Analyzers Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 132 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球生物过程分析仪市场估值为20 亿美元，预计2024 年至2032 年复合年增长率为11.5%。细胞或其细胞。这些分析仪有助于提高生物技术过程的品质、效率和控制，特别是在生物製品生产中。生物技术的不断进步导致了更复杂和自动化的生物过程分析仪的开发，进一步推动了市场的成长。此外，由于生物相似药与生物製剂相比具有成本效益，对生物相似药的需求不断增长，是重要的市场成长动力。

政府的支持和资助也促进了该领域的创新，凸显了这些工具在生物製药产业中日益重要的重要性。根据分析类型，浓度检测成为领先领域，到 2023 年将产生 11 亿美元的收入，预计复合年增长率为 11.6%。包括单株抗体和疫苗在内的生物製品生产依赖于蛋白质、代谢物和细胞密度等关键参数的准确测量。这推动了对能够确保一致的产品品质和法规遵循的分析仪的需求。

依应用，市场分为抗生素、重组蛋白、生物相似药和其他生物製品。到 2023 年，抗生素领域将占据 30.8% 的市场份额，预计在预测期内将以 10.2% 的复合年增长率成长。抗生素生产涉及复杂的微生物发酵过程，需要精确的环境控制。生物製程分析仪配备先进的感测器，有助于监测和维持最佳发酵条件，例如氧气水平、营养供应和温度，最终提高生产效率。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 20亿美元
预测值 54亿美元
复合年增长率 11.5%

就区域成长而言，预计到 2032 年，北美生物过程分析仪市场将达到 20 亿美元。癌症、糖尿病和自体免疫疾病等慢性病的盛行率不断上升，推动了对生物製剂和个人化药物的需求。这反过来又增加了对生物过程分析仪的需求，以改善生产过程并在这些先进疗法的开发中保持法规遵循。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 对生物製药产品的需求不断增长
      • 生物技术和生物加工的进步
      • 对生物相似药的需求不断增加
      • 政府措施和资金不断增加
    • 产业陷阱与挑战
      • 仪器成本高
      • 复杂性和技术专长
  • 成长潜力分析
  • 监管环境
    • 我们
    • 欧洲
    • 亚太地区
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

  • 主要趋势
  • 仪器仪表
  • 耗材及配件

第 6 章：市场估计与预测：按分析类型，2021 - 2032 年

  • 主要趋势
  • 底物分析
  • 代谢物分析
  • 浓度检测

第 7 章：市场估计与预测：按应用分类，2021 - 2032

  • 主要趋势
  • 抗生素
  • 重组蛋白
  • 生物相似药
  • 其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 生物製药公司
  • CRO 和 CMO
  • 研究与学术机构
  • 其他最终用途

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • 4BioCell GmbH & Co. KG
  • Agilent Technologies, Inc.
  • Danaher Corporation
  • Endress+Hauser Group Services AG
  • Eppendorf AG
  • F. Hoffmann-La Roche Ltd.
  • Nova Biomedical
  • Randox Laboratories Ltd.
  • Sartorius AG
  • Solida Biotech GmBH
  • SYSBIOTECH GmbH
  • Thermo Fisher Scientific Inc.
  • Xylem Inc.
简介目录
Product Code: 8765

The Global Bioprocess Analyzers Market was valued at USD 2 billion in 2023 and is projected to grow at a CAGR of 11.5% from 2024 to 2032. Bioprocess analyzers are essential tools used to monitor and optimize bioprocesses, which involve the use of living cells or their components to produce products such as biopharmaceuticals, biofuels, and other biotechnology-driven goods. These analyzers help improve the quality, efficiency, and control of biotechnological processes, especially in biologics production. The ongoing advancements in biotechnology have led to the development of more sophisticated and automated bioprocess analyzers, further fueling market growth. Additionally, the growing demand for biosimilars, owing to their cost-efficiency compared to biologics, is a significant market growth driver.

Government support and funding also foster innovation in this sector, underscoring the increasing importance of these instruments in the biopharmaceutical industry. Based on analysis type, concentration detection emerged as the leading segment, generating USD 1.1 billion in revenue in 2023, with expectations for continued growth at a CAGR of 11.6%. Biologics production, including monoclonal antibodies and vaccines, relies on accurate measurements of critical parameters such as proteins, metabolites, and cell densities. This drives the demand for analyzers that can ensure consistent product quality and regulatory compliance.

By application, the market is divided into antibiotics, recombinant proteins, biosimilars, and other bioproducts. The antibiotics segment accounted for a significant 30.8% market share in 2023 and is anticipated to grow at a 10.2% CAGR over the forecast period. Antibiotic production involves intricate microbial fermentation processes that require precise environmental control. Bioprocess analyzers, equipped with advanced sensors, help monitor and maintain optimal fermentation conditions, such as oxygen levels, nutrient feed, and temperature, ultimately enhancing production efficiency.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$2 Billion
Forecast Value$5.4 Billion
CAGR11.5%

In terms of regional growth, the North American bioprocess analyzers market is expected to reach USD 2 billion by 2032. The U.S. led the regional market in 2023, with a revenue share of USD 712.7 million. The increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders is driving the demand for biologics and personalized medicines. This, in turn, is boosting the need for bioprocess analyzers to improve production processes and maintain regulatory compliance in the development of these advanced therapies.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing demand for biopharmaceutical products
      • 3.2.1.2 Advancements in biotechnology and bioprocessing
      • 3.2.1.3 Increasing demand for biosimilars
      • 3.2.1.4 Rising government initiatives and funding
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of instruments
      • 3.2.2.2 Complexity and technical expertise
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard
  • 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Instruments
  • 5.3 Consumables & accessories

Chapter 6 Market Estimates and Forecast, By Analysis Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Substrate analysis
  • 6.3 Metabolite analysis
  • 6.4 Concentration detection

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Antibiotics
  • 7.3 Recombinant proteins
  • 7.4 Biosimilars
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Biopharmaceutical companies
  • 8.3 CROs & CMOs
  • 8.4 Research & academic institutes
  • 8.5 Other End Use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 4BioCell GmbH & Co. KG
  • 10.2 Agilent Technologies, Inc.
  • 10.3 Danaher Corporation
  • 10.4 Endress+Hauser Group Services AG
  • 10.5 Eppendorf AG
  • 10.6 F. Hoffmann-La Roche Ltd.
  • 10.7 Nova Biomedical
  • 10.8 Randox Laboratories Ltd.
  • 10.9 Sartorius AG
  • 10.10 Solida Biotech GmBH
  • 10.11 SYSBIOTECH GmbH
  • 10.12 Thermo Fisher Scientific Inc.
  • 10.13 Xylem Inc.